SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SUPN • US8684591089

51.18 USD
-0.12 (-0.23%)
At close: Feb 10, 2026
51.05 USD
-0.13 (-0.25%)
Pre-Market: 2/11/2026, 4:19:46 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, SUPN scores 5 out of 10 in our fundamental rating. SUPN was compared to 191 industry peers in the Pharmaceuticals industry. SUPN has an average financial health and profitability rating. SUPN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • SUPN had positive earnings in the past year.
  • SUPN had a positive operating cash flow in the past year.
  • In the past 5 years SUPN has always been profitable.
  • SUPN had a positive operating cash flow in each of the past 5 years.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

  • The Return On Assets of SUPN (-1.35%) is better than 75.39% of its industry peers.
  • SUPN's Return On Equity of -1.82% is fine compared to the rest of the industry. SUPN outperforms 77.49% of its industry peers.
  • The Return On Invested Capital of SUPN (2.34%) is better than 79.58% of its industry peers.
  • SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 12.66%.
Industry RankSector Rank
ROA -1.35%
ROE -1.82%
ROIC 2.34%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • In the last couple of years the Profit Margin of SUPN has declined.
  • The Operating Margin of SUPN (6.08%) is better than 79.58% of its industry peers.
  • SUPN's Operating Margin has declined in the last couple of years.
  • SUPN's Gross Margin of 89.91% is amongst the best of the industry. SUPN outperforms 92.15% of its industry peers.
  • In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
Industry RankSector Rank
OM 6.08%
PM (TTM) N/A
GM 89.91%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, SUPN has more shares outstanding
  • SUPN has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 6.07 indicates that SUPN is not in any danger for bankruptcy at the moment.
  • SUPN has a Altman-Z score of 6.07. This is in the better half of the industry: SUPN outperforms 78.01% of its industry peers.
  • SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.07
ROIC/WACC0.25
WACC9.46%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

  • SUPN has a Current Ratio of 1.80. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.80, SUPN is doing worse than 65.44% of the companies in the same industry.
  • A Quick Ratio of 1.56 indicates that SUPN should not have too much problems paying its short term obligations.
  • SUPN has a Quick ratio of 1.56. This is in the lower half of the industry: SUPN underperforms 61.26% of its industry peers.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.56
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 0.32% over the past year.
  • SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.93% yearly.
  • SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 4.54%.
  • SUPN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.00% yearly.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%

3.2 Future

  • SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.52% yearly.
  • Based on estimates for the next years, SUPN will show a quite strong growth in Revenue. The Revenue will grow by 14.93% on average per year.
EPS Next Y-9.24%
EPS Next 2Y11.67%
EPS Next 3Y15.4%
EPS Next 5Y19.52%
Revenue Next Year9.18%
Revenue Next 2Y15.49%
Revenue Next 3Y16.13%
Revenue Next 5Y14.93%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.51 indicates a correct valuation of SUPN.
  • Compared to the rest of the industry, the Price/Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 85.86% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of SUPN to the average of the S&P500 Index (28.03), we can say SUPN is valued slightly cheaper.
  • With a Price/Forward Earnings ratio of 13.91, SUPN is valued correctly.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 84.29% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of SUPN to the average of the S&P500 Index (27.97), we can say SUPN is valued rather cheaply.
Industry RankSector Rank
PE 16.51
Fwd PE 13.91
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SUPN is valued cheaper than 80.63% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, SUPN is valued a bit cheaper than 79.06% of the companies in the same industry.
Industry RankSector Rank
P/FCF 41.48
EV/EBITDA 19.89
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SUPN's earnings are expected to grow with 15.40% in the coming years.
PEG (NY)N/A
PEG (5Y)2.38
EPS Next 2Y11.67%
EPS Next 3Y15.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SUPN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (2/10/2026, 8:00:00 PM)

Premarket: 51.05 -0.13 (-0.25%)

51.18

-0.12 (-0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-03
Inst Owners104.2%
Inst Owner Change-0.85%
Ins Owners4.26%
Ins Owner Change1.99%
Market Cap2.93B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target62.56 (22.24%)
Short Float %7.51%
Short Ratio6.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)0%
PT rev (3m)5.38%
EPS NQ rev (1m)40.26%
EPS NQ rev (3m)-51.02%
EPS NY rev (1m)-5.46%
EPS NY rev (3m)16.93%
Revenue NQ rev (1m)-0.47%
Revenue NQ rev (3m)-4.69%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)0.81%
Valuation
Industry RankSector Rank
PE 16.51
Fwd PE 13.91
P/S 4.31
P/FCF 41.48
P/OCF 40.83
P/B 2.8
P/tB 9.56
EV/EBITDA 19.89
EPS(TTM)3.1
EY6.06%
EPS(NY)3.68
Fwd EY7.19%
FCF(TTM)1.23
FCFY2.41%
OCF(TTM)1.25
OCFY2.45%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.38
Graham Number35.73
Profitability
Industry RankSector Rank
ROA -1.35%
ROE -1.82%
ROCE 3.81%
ROIC 2.34%
ROICexc 3.16%
ROICexgc 38.99%
OM 6.08%
PM (TTM) N/A
GM 89.91%
FCFM 10.38%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.32%
Cap/Sales 0.16%
Interest Coverage 250
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.56
Altman-Z 6.07
F-Score4
WACC9.46%
ROIC/WACC0.25
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-9.24%
EPS Next 2Y11.67%
EPS Next 3Y15.4%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.18%
Revenue Next 2Y15.49%
Revenue Next 3Y16.13%
Revenue Next 5Y14.93%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year10.08%
EBIT Next 3Y40.06%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%

SUPERNUS PHARMACEUTICALS INC / SUPN FAQ

Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to SUPN.


What is the valuation status for SUPN stock?

ChartMill assigns a valuation rating of 6 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.


What is the profitability of SUPN stock?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for SUPN stock?

The Earnings per Share (EPS) of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to decline by -9.24% in the next year.